

**Clinical Image**

Open Access, Volume 5

**Multi-systemic melioidosis****Naveen kumar\***

Department of Radiodiagnosis, Yashoda Hospital, Secunderabad 500003, Telangana, India.

**\*Corresponding Author: Naveen kumar**Department of Radiodiagnosis, Yashoda Hospital,  
Secunderabad 500003, Telangana, India  
Email: knkumar483@gmail.com

Received: Nov 22, 2024

Accepted: Dec 11, 2024

Published: Dec 18, 2024

Archived: www.jcimcr.org

Copyright: © Kumar N (2024).

DOI: www.doi.org/10.52768/2766-7820/3392

**Abstract**


Melioidosis is a severe infectious disease caused by *Burkholderia pseudomallei*, a Gram-negative bacterium endemic to tropical regions. While it most commonly affects the lungs, melioidosis can present as a multisystemic infection, impacting various organ systems, including the liver, spleen, kidneys, skin, and central nervous system. The clinical manifestations of multisystemic melioidosis are diverse and range from localized abscesses and septicemia to more severe presentations such as pneumonia, Acute Respiratory Distress Syndrome (ARDS), and disseminated infection with organ failure. Risk factors include diabetes mellitus, chronic renal disease, immunosuppression, and trauma, which increase susceptibility to the infection. The pathogenesis of melioidosis is characterized by the ability of *B. pseudomallei* to evade host immune responses, forming intracellular reservoirs and leading to chronic infection. Diagnosis is often challenging due to its non-specific symptoms and requires microbiological culture, PCR, and serological tests. Treatment involves prolonged courses of intravenous and oral antibiotics, with ceftazidime and meropenem being first-line agents. Despite appropriate therapy, the mortality rate remains high, particularly in cases with delayed diagnosis or in immunocompromised patients. Understanding the pathophysiology, risk factors, and optimal management strategies for multisystemic melioidosis is crucial for improving patient outcomes in endemic regions and for travelers to these areas.

**Keywords:** Melioidosis; *Burkholderia pseudomallei*; Multisystemic infection; Sepsis; Pneumonia; Organ failure; Diagnosis; Treatment; Tropical disease.

**Description**

A 25-year-old male who is a farmer presented to the Emergency Department with complaints of fever and headache. The patient does not have any comorbidities. Routine blood tests showed an Erythrocyte Sedimentation Rate (ESR) 36 mm, C-Reactive Protein (CRP) of 42.96 mg/L, and a White Blood Cell (WBC) count of  $11.8 \times 10^3 / \text{mm}^3$  with 75.8% neutrophils, normal platelets, and creatinine. The patient's fasting plasma glucose level was 125 mg/dl. Pulmonary tuberculosis was suspected

initially but sputum culture came as negative. Melioidosis is common in our region so systemic melioidosis was suspected. No genitourinary involvement was noted in the patient. Venous blood was obtained for blood culture and selective media was used for culture. Real-time PCR also confirmed melioidosis. Intravenous Ceftazidime for 4 weeks, followed by oral maintenance therapy with cotrimoxazole for 4 months. Patient was improved after continuous antibiotic therapy.



**Figure 1:** Chest X-Ray showed multiple radio opacities in bilateral lung fields (Panel A, yellow arrow). CT chest showed Patchy subpleural and peri-bronchial consolidations with nodules in bilateral lungs (Panel B & C, red arrows). CT abdomen showed few hypodense lesions in liver (Panel E, orange arrow) and spleen (Panel D, yellow arrow) suggestive of micro-abscesses. Ultrasound abdomen showed few micro-abscesses in spleen (Panel F, yellow arrow). MRI brain with contrast showed Conglomerate peripheral rim enhancing lesions in left frontal lobe (Panel G, black arrow) and multiloculated extra-axial collection with dural enhancement (Panel H, blue arrow). MR spectroscopy revealed large lipid-lactate peaks within the lesion (Panel I, blue arrow). MR perfusion showed no increase in perfusion (Panel J, yellow arrow).